Overview
flowchart TD
companies_janssen["Janssen"]
style companies_janssen fill:#4fc3f7,stroke:#333,color:#000
companies_janssen_0["Company Overview"]
companies_janssen -->|"includes"| companies_janssen_0
style companies_janssen_0 fill:#81c784,stroke:#333,color:#000
companies_janssen_1["Neurodegeneration Pipeline"]
companies_janssen -->|"includes"| companies_janssen_1
style companies_janssen_1 fill:#ef5350,stroke:#333,color:#000
companies_janssen_2["Alzheimers Disease"]
companies_janssen -->|"includes"| companies_janssen_2
style companies_janssen_2 fill:#ffd54f,stroke:#333,color:#000
companies_janssen_3["Parkinsons Disease"]
companies_janssen -->|"includes"| companies_janssen_3
style companies_janssen_3 fill:#ce93d8,stroke:#333,color:#000
companies_janssen_4["Other Neuroscience Programs"]
companies_janssen -->|"includes"| companies_janssen_4
style companies_janssen_4 fill:#4fc3f7,stroke:#333,color:#000
companies_janssen_5["Key Partnerships"]
companies_janssen -->|"includes"| companies_janssen_5
style companies_janssen_5 fill:#81c784,stroke:#333,color:#000
Janssen Pharmaceutical Companies (Johnson & Johnson) is an American pharmaceutical company with a significant neuroscience portfolio focused on developing disease-modifying therapies for Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders["@janssen"].
Company Overview
...Overview
Mermaid diagram (expand to render)
Janssen Pharmaceutical Companies (Johnson & Johnson) is an American pharmaceutical company with a significant neuroscience portfolio focused on developing disease-modifying therapies for Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders["@janssen"].
Company Overview
| Attribute | Value |
|-----------|-------|
| Founded | 1953 (Janssen Pharmaceutica) |
| Headquarters | Beerse, Belgium / Raritan, New Jersey, USA |
| Parent | Johnson & Johnson |
| CEO | Joaquin Duato (J&J Global) |
| Market Cap | ~$400B (J&J, 2025) |
| Employees | ~40,000 (Janssen) |
| R&D Budget | ~$15B annually (J&J total) |
Neurodegeneration Pipeline
Alzheimer's Disease
| Drug | Mechanism | Stage | Status |
|------|-----------|-------|--------|
| JNJ-63733657 | Anti-tau monoclonal antibody | Phase 2 | TauClear program |
| JNJ-2056 | Tau aggregation inhibitor | Phase 1 | Licensed from Cognition Therapeutics |
| ACI-35 | Tau vaccine | Phase 1b | Partnered with AC Immune |
| ACI-35.030 | Next-gen tau vaccine | Preclinical | Enhanced immunogenicity |
JNJ-63733657 (TauClear Program)
JNJ-63733657 is a humanized monoclonal antibody designed to target and clear pathological [tau protein](/proteins/tau) aggregates. Tau pathology correlates strongly with cognitive decline in Alzheimer's disease, making this a key strategic program for Janssen[@jnj].
Mechanism:
- Binds to extracellular tau aggregates in the brain
- Facilitates microglial clearance via Fc-mediated phagocytosis
- Targets multiple tau isoforms and post-translational modifications
Clinical Development:
- Phase 1: Completed in healthy volunteers and AD patients
- Phase 2: Evaluating safety and biomarkers in early AD
- Primary endpoints: Tau PET imaging, cognitive measures (ADAS-Cog13, CDR-SB)
JNJ-2056 (Cognition Therapeutics)
JNJ-2056 is a tau aggregation inhibitor licensed from Cognition Therapeutics. The small molecule prevents the formation of toxic tau oligomers and fibrils, representing a disease-modifying approach[@jnj].
Mechanism:
- Small molecule inhibitor of tau fibril formation
- Oral bioavailability
- Targets multiple tau strains
ACI-35 Partnership (AC Immune)
Janssen partners with AC Immune on the ACI-35 liposomal tau vaccine program. This represents a novel vaccination approach targeting phosphorylated tau epitopes[@immune].
Mechanism:
- Liposome-based delivery system
- Targets phospho-tau (pSer396, pThr181)
- Elicits antibodies against pathological tau species
Parkinson's Disease
| Drug | Mechanism | Stage | Status |
|------|-----------|-------|--------|
| JNJ-67853737 | [Alpha-synuclein](/proteins/alpha-synuclein) antibody | Phase 1 | First-in-human |
| JNJ-79401585 | [LRRK2](/entities/lrrk2) inhibitor | Discovery | Preclinical |
| JNJ-4232 | adenosine A2A receptor antagonist | Phase 2 | Completed |
JNJ-67853737 (Alpha-Synuclein Antibody)
JNJ-67853737 is an anti-alpha-synuclein monoclonal antibody targeting the pathogenic aggregation of alpha-synuclein, the key protein implicated in Parkinson's disease and Lewy body dementia.
Mechanism:
- Targets alpha-synuclein oligomers and pre-fibrillar species
- Prevents cell-to-cell transmission of pathology
- Fc-mediated clearance by [microglia](/cell-types/microglia-neuroinflammation)
Clinical Development:
- Phase 1: Safety and PK in healthy volunteers
- Phase 1b: Exploring biomarker endpoints in PD patients
JNJ-79401585 (LRRK2 Inhibitor)
JNJ-79401585 is a LRRK2 (leucine-rich repeat kinase 2) inhibitor targeting the most common genetic cause of Parkinson's disease. LRRK2 mutations account for 5-10% of familial PD and 1-3% of sporadic PD.
Mechanism:
- Small molecule kinase inhibitor
- Targets pathogenic LRRK2 hyperactivity
- May modify disease progression
Other Neuroscience Programs
| Drug | Indication | Mechanism | Stage |
|------|------------|-----------|-------|
| JNJ-64042056 | Epilepsy | Ion channel modulator | Phase 1 |
| JNJ-6880 | ALS | SOD1 antibody | Discovery |
| JNJ-5405 | MS | Immune modulation | Discovery |
| NfL Assay | Alzheimer's/Parkinson's | Biomarker | Commercial |
Key Partnerships
AC Immune
Janssen's partnership with AC Immune (Switzerland) focuses on tau-targeted therapies. The collaboration includes:
- ACI-35 vaccine (Phase 1b)
- ACI-35.030 next-generation vaccine
- Diagnostic partnerships for tau PET ligands
Cognition Therapeutics
License agreement for JJN-2056, a tau aggregation inhibitor representing an oral small molecule approach to tau pathology.
Biogen
Historical collaborations on Alzheimer's research, including biomarker development and clinical trial methodologies.
Cerevel Therapeutics
Various CNS programs spanning psychiatry, neurology, and rare diseases. Janssen retains options on certain programs.
Research Strategy
Tau Hypothesis Focus
Janssen has prioritized tau-targeted therapies based on:
- Strong correlation between tau pathology and cognitive impairment
- [Amyloid](/mechanisms/amyloid-aggregation)-targeting failures in late-stage clinical trials
- Growing evidence for tau spread as a driver of disease progression
Biomarker-Driven Development
The company employs biomarker strategies including:
- [Tau](/proteins/tau) PET imaging (CFT, FTP ligands)
- CSF tau and p-tau181 measurements
- [Neurofilament light](/biomarkers/neurofilament-light-chain-nfl) chain (NfL) for disease progression
- [Amyloid](/mechanisms/amyloid-aggregation) PET for patient selection
Precision Medicine Approach
Janssen is exploring:
- Genetic subpopulations (APOE4 carriers, LRRK2 mutations)
- Biomarker-positive patient enrichment
- Combination therapy approaches
Financial Highlights (2024)
| Metric | Value |
|--------|-------|
| Janssen Revenue | $56B |
| J&J Total Revenue | $89B |
| J&J R&D Investment | $15B |
| Neuroscience Share | ~12% of pharma |
Janssen represents the largest segment of Johnson & Johnson's pharmaceutical business, with neuroscience being a key growth area despite competitive pressures in the Alzheimer's space.
History
Janssen was founded in 1953 by Dr. Paul Janssen in Beerse, Belgium. Known for its pioneering drug discovery, the company became part of Johnson & Johnson in 1961. Under J&J, Janssen grew to become one of the world's largest pharmaceutical companies.
Neuroscience Heritage
- 1980s: Early CNS drug development (antipsychotics, antidepressants)
- 2000s: Expansion into neurodegeneration
- 2010s: Strategic focus on Alzheimer's and Parkinson's
- 2020s: Tau-centric pipeline development
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
Unknown, Janssen Corporate Website (n.d.)
Unknown, AC Immune Partnership Announcement (n.d.)
Unknown, JNJ-63733657 Clinical Trials Registry (n.d.)
Unknown, Johnson & Johnson Annual Report 2024 (2024)
Unknown, Cognition Therapeutics License Agreement (n.d.)